[Form 4] PUMA BIOTECHNOLOGY INC Insider Trading Activity

Rhea-AI Filing Summary

Puma Biotechnology, Inc. (PBYI) – Form 4 filing

President, CEO and 10% owner Alan H. Auerbach reported two open-market sales of Puma Biotechnology common stock executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on 12-17-2020.

• 07-08-2025: Sold 25,592 shares at $3.533 per share; post-sale direct holdings: 7,202,481 shares.
• 07-09-2025: Sold 21,580 shares at $3.535 per share; post-sale direct holdings: 7,180,901 shares.

Total shares sold: 47,172, representing approximately 0.66% of the executive’s reported direct position. No derivative security transactions were disclosed.

The filing indicates the transactions were made pursuant to a standing 10b5-1 plan, suggesting they were scheduled in advance rather than timed opportunistically.

Positive

• Pre-arranged Rule 10b5-1(c) plan reduces concerns about opportunistic selling.

Negative

• CEO/10% owner sold 47,172 shares, trimming direct holdings to 7.18 million shares.

Insights

Equity Analyst

TL;DR: CEO sold ~47k shares (0.66% stake) under a 10b5-1 plan; minimal dilution signal, neutral impact.

The Form 4 shows two small open-market sales by CEO Alan Auerbach at roughly $3.53 per share, reducing his direct ownership to 7.18 million shares. Because the trades are executed under a 10b5-1 plan adopted in 2020, they appear routine and pre-scheduled, limiting negative signaling. The volume sold is immaterial relative to his overall stake and the company’s float, so the market impact is likely modest. No option exercises, derivative conversions or insider purchases were reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AUERBACH ALAN H

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 2150

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		S(1)		25,592	D	$3.533	7,202,481	D
Common Stock	07/09/2025		S(1)		21,580	D	$3.535	7,180,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 12-17-2020

	/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Puma Biotechnology (PBYI) shares did the CEO sell?

Alan H. Auerbach sold 47,172 common shares over two days.

At what price were the PBYI shares sold?

The shares were sold at an average price of approximately $3.53 per share.

What is the CEO’s remaining direct ownership in PBYI?

After the transactions, he directly owns 7,180,901 common shares.

Were the sales made under a 10b5-1 trading plan?

Yes. The filing states the plan was adopted on 12-17-2020 in accordance with Rule 10b5-1(c).

Did the Form 4 report any derivative transactions?

No derivative security acquisitions or dispositions were reported.